Plant ID: NPO3292
Plant Latin Name: Desmodium styracifolium
Taxonomy Genus: Desmodium
Taxonomy Family: Fabaceae
NCBI TaxonomyDB:
648866
Plant-of-the-World-Online:
n.a.
Diuretic; Febrifuge; VD
Indonesia; India; Malaysia; Vietnam; China; Laos; Thailand
TSHR; NPSR1; | |
BLM; ALOX12; HSD17B1; HSD17B2; HSD17B10; NOX4; TNKS; TNKS2; AOX1; POLB; | |
ACHE; | |
PIM1; MET; FLT3; CDK1; EGFR; AXL; KDR; CDK8; IGF1R; AURKB; CSNK2A1; | |
CA2; CA12; CA14; CA7; CA4; | |
ESR2; ESR1; | |
ESRRB; ESRRA; | |
TYR; | |
MMP9; MMP1; MMP12; MMP2; | |
AHR; TP53; HIF1A; NFKB1; | |
SMN1;SMN2; | |
THPO; |
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
Enzyme_unclassified | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | P37059 | CHEMBL2789 |
Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
Enzyme_unclassified | TNKS | Tankyrase-1 | O95271 | CHEMBL6164 |
Enzyme_unclassified | TNKS2 | Tankyrase-2 | Q9H2K2 | CHEMBL6154 |
Enzyme_unclassified | AOX1 | Aldehyde oxidase | Q06278 | CHEMBL3257 |
Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
Enzyme_unclassified | BLM | Bloom syndrome protein | P54132 | CHEMBL1293237 |
Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
Metallo protease | MMP1 | Matrix metalloproteinase-1 | P03956 | CHEMBL332 |
Metallo protease | MMP12 | Matrix metalloproteinase 12 | P39900 | CHEMBL4393 |
Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
Nuclear hormone receptor subfamily 3 group B | ESRRB | Estrogen-related receptor beta | O95718 | CHEMBL3751 |
Nuclear hormone receptor subfamily 3 group B | ESRRA | Estrogen-related receptor alpha | P11474 | CHEMBL3429 |
Oxidoreductase | TYR | Tyrosinase | P14679 | CHEMBL1973 |
Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
Protein Kinase | EGFR | Epidermal growth factor receptor erbB1 | P00533 | CHEMBL203 |
Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
Protein Kinase | CDK8 | Cell division protein kinase 8 | P49336 | CHEMBL5719 |
Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
Transcription Factor | AHR | Aryl hydrocarbon receptor | P35869 | CHEMBL3201 |
Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 2.617E-11 | 9.497E-08 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
MF | GO:0005488; binding | GO:0019825; oxygen binding | 2.449E-11 | 9.497E-08 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, NOX4 |
MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 3.088E-10 | 6.112E-07 | CA12, CA14, CA2, CA4, CA7 |
MF | GO:0005488; binding | GO:0008270; zinc ion binding | 1.568E-09 | 2.009E-06 | BLM, CA12, CA2, CA4, CA7, ESR1, ESR2, ESRRA, ESRRB, MMP1, MMP12, MMP2, MMP9, TNKS, TP53 |
BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 2.068E-09 | 2.149E-06 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
BP | GO:0008283; cell proliferation | GO:0008284; positive regulation of cell proliferation | 5.121E-09 | 4.130E-06 | ALOX12, CDK1, CSNK2A1, EGFR, ESR1, FLT3, HIF1A, IGF1R, KDR, MMP12, MMP2, MMP9, PIM1, THPO, TSHR |
MF | GO:0005488; binding | GO:0005506; iron ion binding | 8.750E-09 | 6.146E-06 | ALOX12, AOX1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
MF | GO:0005488; binding | GO:0020037; heme binding | 4.322E-08 | 2.075E-05 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, NOX4 |
BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 1.054E-07 | 4.251E-05 | CA12, CA14, CA2, CA4, CA7 |
BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 3.449E-07 | 9.881E-05 | CYP1A2, CYP2C19, CYP2C9 |
MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 3.678E-07 | 1.030E-04 | CYP19A1, CYP1A1, CYP1A2, CYP1B1 |
MF | GO:0005488; binding | GO:0042802; identical protein binding | 4.716E-07 | 1.208E-04 | ACHE, AOX1, BLM, CSNK2A1, EGFR, ESR1, ESR2, FLT3, IGF1R, KDR, MET, MMP9, NFKB1, SMN1, SMN2, TP53, TYR |
MF | GO:0005488; binding | GO:0051879; Hsp90 protein binding | 1.467E-06 | 3.073E-04 | AHR, CSNK2A1, HIF1A, KDR |
BP | GO:0032502; developmental process | GO:0031100; animal organ regeneration | 1.683E-06 | 3.490E-04 | AXL, CDK1, CSNK2A1, EGFR, FLT3 |
MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 1.885E-06 | 3.836E-04 | CYP19A1, CYP1A1, CYP2C19, CYP2C9 |
BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 2.385E-06 | 4.596E-04 | CA12, CA2, CA4, CA7 |
BP | Unclassified; | GO:0044259; multicellular organismal macromolecule metabolic process | 3.110E-06 | 5.788E-04 | HIF1A, MMP1, MMP12, MMP2, MMP9 |
MF | GO:0005488; binding | GO:0005496; steroid binding | 3.110E-06 | 5.788E-04 | ESR1, ESR2, ESRRA, ESRRB, HSD17B1 |
BP | GO:0009987; cellular process | GO:0071407; cellular response to organic cyclic compound | 3.537E-06 | 6.418E-04 | BLM, CYP1A1, CYP1B1, EGFR, ESR1, FLT3, NFKB1, NOX4 |
BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 3.751E-06 | 6.670E-04 | CYP1A2, CYP2C19, CYP2C9 |
BP | GO:0008152; metabolic process | GO:0006367; transcription initiation from RNA polymerase II promoter | 3.891E-06 | 6.779E-04 | CDK1, CDK8, ESR1, ESR2, ESRRA, ESRRB |
BP | GO:0008152; metabolic process | GO:0006703; estrogen biosynthetic process | 4.868E-06 | 8.216E-04 | CYP19A1, HSD17B1, HSD17B2 |
BP | GO:0009987; cellular process | GO:0030522; intracellular receptor signaling pathway | 6.519E-06 | 1.051E-03 | AHR, ESR1, ESR2, ESRRA, ESRRB, PIM1 |
MF | GO:0060089; molecular transducer activity | GO:0038052; RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding | 6.835E-06 | 1.083E-03 | ESR1, ESR2 |
BP | GO:0050896; response to stimulus | GO:0071417; cellular response to organonitrogen compound | 8.408E-06 | 1.254E-03 | BLM, EGFR, IGF1R, MMP2, NFKB1, NOX4, TP53, TSHR |
BP | Unclassified; | GO:0044236; multicellular organism metabolic process | 8.698E-06 | 1.280E-03 | HIF1A, MMP1, MMP12, MMP2, MMP9 |
BP | GO:0008152; metabolic process | GO:0016579; protein deubiquitination | 9.183E-06 | 1.333E-03 | CDK1, ESR1, HIF1A, POLB, TNKS, TNKS2, TP53 |
BP | GO:0065007; biological regulation | GO:1904355; positive regulation of telomere capping | 1.149E-05 | 1.583E-03 | AURKB, TNKS, TNKS2 |
BP | GO:0022414; reproductive process | GO:0001892; embryonic placenta development | 1.915E-05 | 2.383E-03 | EGFR, ESRRB, HIF1A |
BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 2.047E-05 | 2.516E-03 | CA2, CA7 |
BP | GO:0008152; metabolic process | GO:0045944; positive regulation of transcription from RNA polymerase II promoter | 2.199E-05 | 2.675E-03 | AHR, CDK8, EGFR, ESR1, ESRRA, ESRRB, HIF1A, MET, MMP12, NFKB1, TNKS, TP53 |
BP | GO:0050896; response to stimulus | GO:0055093; response to hyperoxia | 2.230E-05 | 2.698E-03 | CYP1A1, POLB, TP53 |
BP | GO:0008152; metabolic process | GO:0030574; collagen catabolic process | 2.591E-05 | 3.066E-03 | MMP1, MMP12, MMP2, MMP9 |
BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 2.959E-05 | 3.409E-03 | CYP1A1, CYP1A2, CYP1B1 |
BP | GO:0008152; metabolic process | GO:0070213; protein auto-ADP-ribosylation | 4.087E-05 | 4.378E-03 | TNKS, TNKS2 |
BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 4.087E-05 | 4.378E-03 | CYP1A1, CYP1A2 |
MF | GO:0005488; binding | GO:0034056; estrogen response element binding | 4.087E-05 | 4.378E-03 | ESR1, ESR2 |
MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 4.087E-05 | 4.378E-03 | CYP1A2, CYP2C9 |
BP | GO:0009987; cellular process | GO:0051897; positive regulation of protein kinase B signaling | 4.956E-05 | 5.091E-03 | AXL, EGFR, MET, NOX4, THPO |
BP | GO:0009987; cellular process | GO:0022617; extracellular matrix disassembly | 5.596E-05 | 5.590E-03 | MMP1, MMP12, MMP2, MMP9 |
BP | GO:0050896; response to stimulus | GO:0033273; response to vitamin | 6.476E-05 | 6.268E-03 | CYP1A1, EGFR, TP53, TYR |
BP | GO:0009987; cellular process | GO:0071276; cellular response to cadmium ion | 7.398E-05 | 7.004E-03 | CYP1A2, EGFR, MMP9 |
MF | GO:0005488; binding | GO:0042562; hormone binding | 7.454E-05 | 7.026E-03 | ACHE, EGFR, HSD17B1, IGF1R |
MF | GO:0005488; binding | GO:0001047; core promoter binding | 7.971E-05 | 7.417E-03 | ESR1, ESR2, ESRRB, MMP12, TP53 |
BP | GO:0008152; metabolic process | GO:2000377; regulation of reactive oxygen species metabolic process | 8.197E-05 | 7.596E-03 | CYP1B1, EGFR, HIF1A, NOX4, TP53 |
MF | GO:0005488; binding | GO:0005524; ATP binding | 8.818E-05 | 8.034E-03 | AURKB, AXL, BLM, CDK1, CDK8, CSNK2A1, EGFR, FLT3, IGF1R, KDR, MET, PIM1, TP53 |
BP | GO:0008152; metabolic process | GO:1903580; positive regulation of ATP metabolic process | 9.794E-05 | 8.776E-03 | CDK1, ESRRB, HIF1A |
BP | GO:0065007; biological regulation | GO:0032212; positive regulation of telomere maintenance via telomerase | 9.794E-05 | 8.776E-03 | AURKB, TNKS, TNKS2 |
BP | GO:0048511; rhythmic process | GO:0048511; rhythmic process | 9.901E-05 | 8.836E-03 | AHR, AXL, CSNK2A1, EGFR, ESR1, TP53 |
BP | GO:0050896; response to stimulus | GO:0009611; response to wounding | 1.075E-04 | 9.476E-03 | ACHE, CDK1, CYP1A1, EGFR, TP53 |
Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|---|
09160 Human Diseases | 09161 Cancers | hsa05205 | Proteoglycans in cancer | 2.015E-09 | 1.371E-07 | MMP2, KDR, TP53, HIF1A, ESR1, MMP9, MET, EGFR, IGF1R |
09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 2.960E-09 | 1.371E-07 | HSD17B1, HSD17B2, CYP1A1, CYP1B1, CYP19A1, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 5.247E-08 | 1.428E-06 | FLT3, MMP1, MMP2, HIF1A, MET, TP53, MMP9, EGFR, NFKB1, IGF1R |
09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 5.330E-10 | 7.408E-08 | CA12, CA2, CA4, CA7, CA14 |
09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 7.423E-09 | 2.579E-07 | HSD17B1, CYP1A2, HSD17B2, CYP1A1, CYP1B1, CYP19A1 |
09160 Human Diseases | 09161 Cancers | hsa05219 | Bladder cancer | 6.164E-08 | 1.428E-06 | MMP1, MMP2, MMP9, TP53, EGFR |
09160 Human Diseases | 09161 Cancers | hsa05230 | Central carbon metabolism in cancer | 7.557E-07 | 1.501E-05 | FLT3, TP53, MET, HIF1A, EGFR |
09150 Organismal Systems | 09152 Endocrine system | hsa04915 | Estrogen signaling pathway | 5.264E-06 | 7.317E-05 | MMP2, ESR1, MMP9, EGFR, ESR2 |
09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 3.202E-06 | 4.946E-05 | CYP1A2, CYP1A1, AOX1, CYP1B1 |
09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 2.075E-06 | 3.605E-05 | CYP2C9, CYP1A2, CYP1A1, CYP1B1, CYP2C19 |
09160 Human Diseases | 09161 Cancers | hsa05206 | MicroRNAs in cancer | 9.818E-06 | 1.137E-04 | PIM1, CYP1B1, TP53, MMP9, MET, EGFR, NFKB1 |
09160 Human Diseases | 09161 Cancers | hsa05202 | Transcriptional misregulation in cancer | 6.292E-06 | 7.950E-05 | FLT3, TP53, MMP9, MET, NFKB1, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05218 | Melanoma | 3.212E-05 | 2.977E-04 | TP53, MET, EGFR, IGF1R |
09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 2.264E-05 | 2.420E-04 | CYP2C9, CYP1A2, CYP1A1, AOX1 |
09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00982 | Drug metabolism - cytochrome P450 | 2.869E-05 | 2.848E-04 | CYP2C9, CYP1A2, AOX1, CYP2C19 |
09160 Human Diseases | 09161 Cancers | hsa05215 | Prostate cancer | 7.804E-05 | 5.709E-04 | TP53, EGFR, NFKB1, IGF1R |
09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 3.585E-05 | 3.093E-04 | CYP2C9, CYP1A2, CYP1A1, CYP1B1 |
09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04520 | Adherens junction | 3.782E-05 | 3.093E-04 | CSNK2A1, MET, EGFR, IGF1R |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04151 | PI3K-Akt signaling pathway | 2.218E-04 | 1.468E-03 | KDR, TP53, MET, EGFR, NFKB1, IGF1R |
Unclassified | Unclassified | hsa01100 | Metabolic pathways | 2.364E-04 | 1.494E-03 | CYP2C9, HSD17B1, HSD17B2, CYP1A2, CYP1A1, AOX1, ALOX12, CYP2C19, TYR, CYP19A1, HSD17B10 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04066 | HIF-1 signaling pathway | 1.376E-04 | 9.566E-04 | HIF1A, EGFR, NFKB1, IGF1R |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04014 | Ras signaling pathway | 2.768E-04 | 1.673E-03 | KDR, MET, EGFR, NFKB1, IGF1R |
09130 Environmental Information Processing | 09133 Signaling molecules and interaction | hsa04060 | Cytokine-cytokine receptor interaction | 5.616E-04 | 3.002E-03 | THPO, FLT3, KDR, MET, EGFR |
09160 Human Diseases | 09161 Cancers | hsa05221 | Acute myeloid leukemia | 4.148E-04 | 2.402E-03 | FLT3, PIM1, NFKB1 |
09160 Human Diseases | 09161 Cancers | hsa05214 | Glioma | 6.104E-04 | 3.142E-03 | TP53, EGFR, IGF1R |
09100 Metabolism | 09103 Lipid metabolism | hsa00590 | Arachidonic acid metabolism | 5.313E-04 | 2.954E-03 | CYP2C9, ALOX12, CYP2C19 |
09160 Human Diseases | 09161 Cancers | hsa05212 | Pancreatic cancer | 6.383E-04 | 3.169E-03 | TP53, EGFR, NFKB1 |
09160 Human Diseases | 09167 Infectious diseases | hsa05169 | Epstein-Barr virus infection | 1.742E-03 | 7.062E-03 | CSNK2A1, CDK1, TP53, NFKB1 |
09160 Human Diseases | 09167 Infectious diseases | hsa05168 | Herpes simplex infection | 1.261E-03 | 5.656E-03 | CSNK2A1, CDK1, TP53, NFKB1 |
09150 Organismal Systems | 09152 Endocrine system | hsa04917 | Prolactin signaling pathway | 8.230E-04 | 3.813E-03 | ESR1, NFKB1, ESR2 |
09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04510 | Focal adhesion | 1.742E-03 | 7.062E-03 | KDR, MET, EGFR, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05203 | Viral carcinogenesis | 1.838E-03 | 7.097E-03 | POLB, CDK1, TP53, NFKB1 |
09160 Human Diseases | 09167 Infectious diseases | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 6.966E-04 | 3.339E-03 | MET, EGFR, NFKB1 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04015 | Rap1 signaling pathway | 2.042E-03 | 7.670E-03 | KDR, MET, EGFR, IGF1R |
09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 2.183E-03 | 7.987E-03 | MMP2, PIM1, NFKB1 |
09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 5.447E-05 | 4.206E-04 | CYP2C9, CYP1A2, CYP2C19 |
09150 Organismal Systems | 09149 Aging | hsa04211 | Longevity regulating pathway - mammal | 1.778E-03 | 7.062E-03 | TP53, NFKB1, IGF1R |
09150 Organismal Systems | 09155 Excretory system | hsa04964 | Proximal tubule bicarbonate reclamation | 1.559E-03 | 6.770E-03 | CA2, CA4 |
ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
---|---|---|---|
G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; |
C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | ESR1; IGF1R; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; |
C00-D49: Neoplasms | CLL | NA | FLT3; |
C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A; EGFR; |
C00-D49: Neoplasms | Lung cancer | C33-C34 | EGFR; MMP2; |
K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET; |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R; |
H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R; |
C00-D49: Neoplasms | Thyroid cancer | C73 | KDR; TSHR; |
L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ESRRA; |
L00-L99: Diseases of the skin and subcutaneous tissue | Dermatological disease | L00-L99 | ESRRA; |
C00-D49: Neoplasms | Bladder cancer | C67 | EGFR; CYP19A1; |
C00-D49: Neoplasms | Liver cancer | C22 | IGF1R; KDR; |
C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53; |
I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET; |
H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53; |
C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | KDR; EGFR; TP53; |
C00-D49: Neoplasms | Head and neck squamous cell carcinoma | C44 | EGFR; |
A00-B99: Certain infectious and parasitic diseases | Cryptosporidium infection | A07.2 | EGFR; |
C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR; |
C00-D49: Neoplasms | Brain cancer | C71, D33 | ESR1; EGFR; |
C00-D49: Neoplasms | Breast cancer | C50 | ESR1; CDK1; IGF1R; KDR; FLT3; EGFR; CYP19A1; |
N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1; |
C00-D49: Neoplasms | Pancreatic cancer | C25 | KDR; FLT3; EGFR; MMP2; |
K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | ESRRA; EGFR; |
C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR; |
W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR; |
C00-D49: Neoplasms | Cancer | C00-C96 | ESR1; PIM1; MET; CDK1; IGF1R; KDR; CSNK2A1; NFKB1; FLT3; ACHE; HIF1A; MMP9; EGFR; TP53; MMP2; |
C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1; |
C00-D49: Neoplasms | Inflammatory breast cancer | C50 | EGFR; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; |
N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1; |
NA: NA | Gonorrheal vaginitis | NA | ESR1; |
NA: NA | GIST | NA | FLT3; |
H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE; |
C00-D49: Neoplasms | Glioma | C71 | KDR; EGFR; |
C00-D49: Neoplasms | Gliosarcoma | NA | FLT3; |
C00-D49: Neoplasms | Glioblastoma multiforme | C71 | EGFR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | MMP1; |
L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | EGFR; |
C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; IGF1R; KDR; AXL; EGFR; |
I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | KDR; |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cachexia | R64 | ESRRA; |
C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3; |
C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR; |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE; |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE; |
C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; |
L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1; |
NA: NA | Edema | NA | CA2; |
C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR; |
N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R; |
N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | ESR1; |
N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1; |
K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; |
NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE; |
C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1; |
I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ESR1; NPSR1; |
L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | ESR1; ESRRA; MMP2; |
C00-D49: Neoplasms | Malignant tumor | C00-C75, C7A, C7B | EGFR; |
C00-D49: Neoplasms | Melanoma | C43 | KDR; EGFR; TYR; |
C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR; |
L00-L99: Diseases of the skin and subcutaneous tissue | Melasma | L81.1 | TYR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1; |
C00-D49: Neoplasms | Leukemia | C90-C95 | ESR1; FLT3; |
E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | ESRRA; |
A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1; |
C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R; |
I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9; |
C00-D49: Neoplasms | Locally advanced head and neck cancer | C07-C14, C32, C33 | EGFR; |
N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | ESR1; |
C00-D49: Neoplasms | Esophageal cancer | C15 | EGFR; |
I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | EGFR; |
G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE; |
I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | MMP12; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1; |
J00-J99: Diseases of the respiratory system | Asthma | J45 | MMP12; ESRRA; |
C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | ESRRA; MMP1; TYR; |
Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | MMP2; |
Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | ACHE; |
I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR; |
I00-I99: Diseases of the circulatory system | Aortic aneurysm | I71 | MMP12; |
J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | ESRRA; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | ESR1; |
C00-D49: Neoplasms | Ovarian cancer | C56 | KDR; EGFR; MMP2; |
K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE; |
G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ESR1; |
C00-D49: Neoplasms | Multiple myeloma | C90 | IGF1R; AHR; |
G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | ESRRA; |
C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR; |
NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | ESR1; |
C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53; |
NA: NA | Menopausal disorder | NA | ESR1; |
G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; |
G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ESR1; CDK1; IGF1R; ACHE; |
A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE; |
H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA4; ACHE; CA2; |
H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | FLT3; EGFR; |
C00-D49: Neoplasms | AML | NA | KDR; FLT3; |
N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1; |
I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2; |
N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1; |
I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; |
C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE; |
C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR; |
C00-D49: Neoplasms | Solid tumours | C00-D48 | MET; AURKB; IGF1R; KDR; FLT3; HIF1A; MMP9; EGFR; TP53; MMP2; |
J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3; |
C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET; |
NA: NA | Postmenopausal disorder | NA | ESR1; |
N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | ESRRA; MMP1; |
C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; |
C00-D49: Neoplasms | Advanced cancers | C00-C96 | EGFR; |
C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR; |
C00-D49: Neoplasms | Advanced prostate cancer | C61 | ESR1; |
N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1; |
C00-D49: Neoplasms | Gastric cancer | C16 | KDR; EGFR; |
N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1; |
N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; |
I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A; |
C00-D49: Neoplasms | Colon cancer | C50 | FLT3; EGFR; |
C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ESR1; |
G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2; |
NA: NA | HIV infections | NA | AHR; |
C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | ESR1; |
L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | TYR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1; |
H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1; |
C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR; |
C00-D49: Neoplasms | Prostate cancer | C61 | ESR1; FLT3; EGFR; |
N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1; |
Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | ESR1; |
C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | AURKB; FLT3; TP53; |
C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3; |
C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR; |
C00-D49: Neoplasms | Metastasis | C00-C97 | AXL; |
C00-D49: Neoplasms | Glioblastoma | NA | FLT3; |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1; |
A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1; |
C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53; |
I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53; |
C00-D49: Neoplasms | Renal cell carcinoma | NA | KDR; MMP2; |
C00-D49: Neoplasms | Renal cancer | C64 | KDR; |
C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR; EGFR; |
N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE; |
C00-D49: Neoplasms | Urethral cancer | NA | EGFR; |
K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MMP9; |
NA: NA | Upper abdominal bloating | NA | ACHE; |
C00-D49: Neoplasms | Refractory breast cancer | C50 | EGFR; |
A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE; |
C00-D49: Neoplasms | Hematological malignancies | C81-C86 | AURKB; TP53; |
A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3; |
Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1; |
C00-D49: Neoplasms | Colorectal cancer | C18-C21 | IGF1R; KDR; FLT3; MMP9; EGFR; TP53; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ESR1; |
C00-D49: Neoplasms | Non-small-cell lung cancer | NA | EGFR; |
G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; |
K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET; |
H00-H59: Diseases of the eye and adnexa | Choroidal neovascularisation | H35 | ESRRA; |
H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; |
C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | MMP12; |
NA: NA | Hematopoietic stem cell transplantation | NA | FLT3; |
C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; KDR; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Vulnerary | S00-T98 | EGFR; |
J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | MMP12; |
C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | EGFR; |